This study demonstrated the activity and efficacy of a novel investigational CDK4/6 inhibitor GLR2007 in preclinical models of solid tumors including GBM, and lung, liver, breast, and colorectal cancers. This evidence concerns the gene CDK4 and glioblastoma.